RYZ801
PreclinicalSmall molecule
RYZ801 is one of 13 small molecule programs targeting Hepatocellular Carcinoma (HCC). It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Hepatocellular Carcinoma (HCC)
#DrugCompanyPhaseTrials
1Avastin
RochePhase 2
Yervoy
Bristol-Myers SquibbPhase 2
Opdivo
Bristol-Myers SquibbPhase 2
Beyfortus
BeiGenePhase 2
Tecentriq
RochePhase 2
Farxiga
AstraZenecaPhase 2
Zofran
NovartisPhase 2
Actemra
RochePhase 2
Nitrostat
VViatris Specialty LLC
Phase 2
Navmi
SSummit Therapeutics
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RYZ801. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- RRayzeBio, Inc.